Healthcare Cloud spending will fuel further growth in Telemedicine even after the Covid-19 crisis, because of its huge ‘convenience’ factor believes the creator of the HAN-GINS Indxx Healthcare Innovation UCITS ETF (WELL).
The number of telemedicine patients in the US is expected to treble by 2023 to 64mln from 21mln in 2019, with the annual growth rate in 2020 almost 100%.
The WELL health ETF also expects Gene Sequencing and Robotics players (Intuitive Surgical) to enjoy significant growth as genomics become increasingly mainstream across the medical field leading to fewer infections and reduced hospital stays.
Healthcare Trackers/Wearables are increasingly popular too – the ETF expects Big Tech to become increasingly active in this space, while many mainstream medical insurance plans now include insurance for Telemedicine.
Anthony Ginsberg, co-creator of WELL, said: “The Covid-19 crisis is forcing healthcare systems to innovate, fast-tracking digital health adoption rates. Cloud-based hospital spending is enjoying a boom and enabling new health-tech products and services. Gene Sequencing and Biotech areas are seen as increasingly mainstream for healthcare solutions such as vaccines.
“Remote Wearables/Trackers and Telemedicine are experiencing a huge surge due to private and government insurance now covering such procedures. Telemedicine is on track to grow by over 30% annualised between 2021-2025.
HAN-GINS Indxx Healthcare Innovation UCITS ETF (WELL) has delivered a return of 35.48% over the past 12 months.
It tracks the Indxx Advanced Life Sciences & Smart Healthcare Thematic Index (Net Total Return).